Viewing Study NCT06022757

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:07 PM
Ignite Modification Date: 2026-01-01 @ 9:09 AM
Study NCT ID: NCT06022757
Status: RECRUITING
Last Update Posted: 2024-02-23
First Post: 2023-08-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Sponsor: Evopoint Biosciences Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma View
None Squamous Cell Carcinoma of Head and Neck View
None Urothelial Carcinoma View
None Prostate Cancer View
None Small-cell Lung Cancer View
None Non-small Cell Lung Cancer View
None Cervical Cancer View
None Other Solid Tumors View
Keywords:

Keywords

Keyword Brief Keyword Text View
None XNW5004 View
None EZH2 inhibitor View
None KEYTRUDA® (pembrolizumab) View
None immune checkpoint inhibitors View